R. Jacob Volgelstein

Proto Axiom Pty Ltd. is an Australian company that focuses on investing in pre-clinical biotech companies to expand the growing bioscience industry. The company is based in Melbourne, Australia. The company has a disciplined and repeatable approach to investing by centralizing a world-class R & D team and licensing leading scientific IP to commercialize it. The company has an executive leadership with over 40 years of experience and a world-renowned scientific team with education from top academic institutions from across the globe, including Harvard. Despite Australia's strong biotech credentials, there is a distinct lack of early-stage venture capital funds to support and commercialize this science. The company was founded in 2021, and the CEO is Anthony Liveris.